Plasma therapy trial aims to tame deadly sepsis blood crisis
NCT ID NCT04580563
Summary
This study tested whether a special, standardized plasma product (OctaplasLG®) could help control dangerous blood clotting problems in people with septic shock. 60 critically ill adult patients with sepsis-induced coagulopathy were randomly assigned to receive either the plasma product or a saline placebo. The main goal was to see if this treatment approach was practical to study, while also checking effects on patient survival and organ function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67000, France
Conditions
Explore the condition pages connected to this study.